ADMA Biologics vs Iovance Biotherapeutics
ADMA and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADMA and IOVA compare
ADMA Biologics and Iovance Biotherapeutics are about the same size, with market caps of $3.1B and $3.4B.
Iovance Biotherapeutics grew revenue faster over the last twelve months (34.5% versus 8.0% for ADMA Biologics).
ADMA Biologics keeps more of each dollar of sales as profit, with a net margin of 33.0% compared with −89.1% at Iovance Biotherapeutics.
ADMA Biologics scores higher on the StockData Score (17 against 9 for Iovance Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADMA | IOVA |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $3.4B |
| Share price | $13.63 | $7.53 |
| Change, 1 year | −12.4% | 205% |
| Change, 5 years | 840% | −59.3% |
| Beta (5Y) | 1.48 | 1.45 |
| Employees | 647 | 975 |
| StockData Score | ||
| Total score | 17 (better) | 9 |
| Valuation score | 5 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 19.5× | – |
| P/S | 6.0× (better) | 10.5× |
| P/B | 7.5× | 4.6× (better) |
| EV/EBITDA | 13.4× | – |
| P/FCF | 26.2× | – |
| FCF yield | 3.8% (better) | −8.7% |
| Fair value | $18.83 | $4.03 |
| Margin of safety | 27.6% (better) | −86.8% |
| Growth | ||
| Revenue growth (TTM) | 8.0% | 34.5% (better) |
| Revenue growth, 5Y average | 64.6% | – |
| Net income growth (TTM) | −19.1% | – |
| EPS growth (TTM) | −17.6% | – |
| Profitability | ||
| Gross margin | 64.7% (better) | 48.4% |
| Operating margin | 43.8% (better) | −92.7% |
| Net margin | 33.0% (better) | −89.1% |
| FCF margin | 22.7% (better) | −91.2% |
| Return on equity | 41.9% (better) | −40.4% |
| Return on invested capital | 45.1% (better) | −57.0% |
| Financial health | ||
| Debt / equity | 0.48 (better) | 0.00 |
| Net debt / EBITDA | 0.26 | – |
| Interest coverage | 25.4× | – |
| Current ratio | 6.97 (better) | 4.35 |
| Altman Z-score | 9.10 (better) | 6.70 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 6.1% (better) | −8.6% |
| Shareholder yield | 6.1% (better) | −8.6% |
| Ownership | ||
| Held by institutions | 91.8% | 63.3% |
| Held by insiders | 2.9% | 0.39% |
| Insider net buying, 12 months | −$3.0M | – |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 8.3% | 14.4% |
Go deeper
- ADMA stock overview
- ADMA income statement
- ADMA valuation and score
- IOVA stock overview
- IOVA income statement
- IOVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.